CIRM’s board approved new and amended funding programs to advance stem cell & gene therapy research

The updated funding concepts include expanded support for large collaborative teams and pairs of investigators, pre-Investigational New Drug (pre-IND) or IND-enabling research, and late-stage clinical trials. With the approval of the new funding and amended programs, CIRM is deepening its commitment to advancing stem cell and gene therapy research in California. “These funding decisions exemplify CIRM’s dedication to driving impactful, patient-focused research that addresses critical unmet medical needs," said CIRM Chief Science Officer, Rosa Canet-Avilés, PhD. CIRM will post the final program announcements and details on its website throughout the spring and fall. Researchers can learn more and sign up for email updates on our website.